@article{oai:repo.qst.go.jp:00055520,
 author = {吉川, 京燦 and 石川, 博之 and 佐合, 賢治 and 田村, 克巳 and 松野, 典代 and 神立, 進 and 溝江, 純悦 and 須原, 哲也 and 鈴木, 和年 and 辻井, 博彦 and 吉川 京燦 and 石川 博之 and 佐合 賢治 and 田村 克巳 and 松野 典代 and 神立 進 and 溝江 純悦 and 須原 哲也 and 鈴木 和年 and 辻井 博彦},
 issue = {HIMAC-115},
 journal = {放射線医学総合研究所重粒子線がん治療装置等共同利用研究報告書},
 month = {May},
 note = {Objectives: Malignant melanoma in head and neck region accounts for 30 to 56 percent of all malignant melanoma in Japan, and especially nasal malignant melanoma is very rare among them. The carbon ion radiotherapy(CIRT) has been introduced in our institute, and we have treated the nasal malignant melanoma using carbon ion beam, We evaluated whether C-11 methionine(MET) uptake and its  change after CIRT were the early survival factors in patients with nasal malignant melanoma.
Methods: MET-PET was prospectively performed in 28 patients with nasal malignant melanoma before CIRT, and 25 patients of them were also received MET-PET after CIRT. Patients were followed for 4.8 to 35.5 months(mean: 16.2 months) after CIRT.Tumor MET uptake was measured with the semi-quantitative tumor-to muscle ratio(TMR). The MET uptake in the tumor and the result of short-term prognosis were entered into Kaplan-Meier analysis. The relationship between the change of MET uptake after CIRT and the result of local cantrol rate, CR(complete remission) or PR(partial response) group and SD(stable disease) group, was also analyzed.
Results: The overall median survival time was 12.9 months. Patients with a baseline TMR of <= 10.7 had a significantly better survival than patients with a baseline TMR > 10.7(2-year survival rate: 68.8% versus 31.2%, P=0.038). Patients with a post CIRT TMR <= 7.0 had a better survival than that with a post CIRT TMR > 7.0(2-year survival rate: 79.0% versus 21.0%, P=0.043). No statistically significant difference of survival rate was observed between any two patient groups of post-therapeutic MET uptake change. To significantly higher local control rate was observed in patients with post-therapeutic MET uptake change of > 30% than patients in lower change group(2-year local control rate: 74.1% versus 25.9%, P=0.008).
Conclusions: MET uptake, as measured by either baseline or post CIRT TMR was an indepedent predictor of survival in patients with nasal malignant melanoma treated by carbon ion radiotherapy, while post-therapeutic MET uptake change might have potential value for predicting local control.},
 pages = {11--12},
 title = {メチオニンPETによる鼻腔悪性黒色腫の重粒子線治療前後評価と予後},
 year = {2006}
}